Sign In
Buy SLRX
$0.84
+0 (+0%)
At Close: Apr 14, 2026
Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress
08:01am, Tuesday, 26'th Oct 2021
Conference Call and Live Audio Webcast Scheduled for Thursday, November 4, 2021, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, November 4, 2021, 5:00 p.m. ET
HOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric canc
Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference
08:01am, Tuesday, 05'th Oct 2021
HOUSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedi
HOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric can
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
07:01am, Tuesday, 28'th Sep 2021
HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, ped
Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership
07:33am, Wednesday, 22'nd Sep 2021
HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedi
Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index
07:33am, Monday, 20'th Sep 2021
HOUSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, ped
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
08:03am, Wednesday, 15'th Sep 2021
HOUSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, ped
Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
08:13am, Wednesday, 08'th Sep 2021
HOUSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, ped
Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational
02:00pm, Thursday, 12'th Aug 2021
HOUSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedi
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2021 Results - Earnings Call Transcript
08:57am, Sunday, 08'th Aug 2021
Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q2 2021 Results - Earnings Call Transcript
Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
07:32am, Thursday, 05'th Aug 2021
Clinical Trial in Hematologic Cancers Initiated and Initial Patients Enrolled in Expanded Sarcoma Clinical Trial; Multiple Potential Data Readouts Expected in 2021 and 2022
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
07:33am, Thursday, 29'th Jul 2021
Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET
Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets Summit
08:05am, Wednesday, 14'th Jul 2021
Dr. Duncan will discuss seclidemstat's potential in treating FET-rearranged sarcomas Dr. Duncan will discuss seclidemstat's potential in treating FET-rearranged sarcomas
Clinical Trial Now Expands to Nine U.S. Trial Sites Clinical Trial Now Expands to Nine U.S. Trial Sites
